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Case Report
Inflammatory Myofibroblastic Tumor of
the Bladder With FN1-ALK Gene
Fusion: Different Response to ALK
Inhibition
Sophie Reinhart, Yasmin Trachsel*, Christine Fritz, Ulrich Wagner,
Beata Bode-Lesniewska, Hubert John, and Miklos Pless
Inflammatory myofibroblastic tumors are rare tumors with an ALK (anaplastic lymphoma kinase) gene rearrangement in
up to 65% of all cases. In our patient, the tumor was not primary resectable due to its extension. Under neoadjuvant
treatment with the first generation ALK inhibitor crizotinib no tumor response was seen, but the following therapy with
the next generation ALK inhibitor lorlatinib led to a rapid and deep response, enabling a complete tumor resection by
partial cystectomy. Our case indicates that ALK positive inflammatory myofibroblastic tumors which do not respond to
ALK inhibition with crizotinib can be successfully treated with newer agents. UROLOGY 00: 1−4, 2020. © 2020
Elsevier Inc.
I
nflammatory myofibroblastic tumors (IMTs) are rare
tumors, occurring mainly in the abdominal cavity, ret-
roperitoneum, pelvis, lung, head and neck, and less
frequently in the gastrointestinal tract, pancreas, bladder
and uterus.1,2 Children and young adults are affected most
often, but IMTs may occur along the entire range of age,
with a slight predominance for women.1-5 Histologically,
IMTs consist of a loosely fascicular proliferation of spindle
cells with myobroblastic phenotype, variable cellularity,
stromal edema and myxoid change as well as varying
inflammatory infiltrate of plasma cells, lymphocytes, and
eosinophilic granulocytes.2-6 The overall recurrence rate
of IMTs is about 20%, but seems much higher for abdomi-
nal and pelvic IMTs (up to 85%), and conversely lower in
IMTs of the lung (<2%) and bladder (<4%).2-4,6 Metasta-
ses (mainly in lung, brain, liver, and bone) occur in <5%
of the cases.1,2,4 In 50%-65% of all IMTs, an anaplastic
lymphoma kinase (ALK) gene rearrangement can be
detected, leading to a constitutive activation of the ALK
tyrosine kinase, causing uncontrolled cell proliferation.2-5
The high frequency of ALK alterations in IMTs makes it
a diagnostic marker. In addition, there seem to be clinical
and biological differences between ALK positive and
negative IMTs: ALK positive IMTs are more frequent in
females and younger patients.4 Abdominal IMTs showed
more ALK positivity than pulmonary IMTs, and ALK
positive IMTs were reported to have a higher recurrence
rate, whereas ALK negative IMTs were associated with a
higher frequency of metastases.2,3
For IMTs of the urinary bladder, complete surgical
resection is the targeted therapeutic strategy and the
only known curative treatment. A study that reviewed
120 cases of IMTs of the bladder reported sufficient pri-
mary treatment with transurethral resection of bladder
tumor (TURBT) in 60.8%, followed by partial cystec-
tomy in 29.2% and radical cystectomy in 9.2% in cases
with residual tumor.4 With the possibility of a targeted
therapy against ALK alterations with kinase inhibition,
a new promising therapy option is now available.
CASE PRESENTATION
We present the case of a 43-year-old woman who suffered
from dysuria and macrohematuria for 5 months. Cystos-
copy showed an extensive solid and papillary tumor of the
anterior wall of the urinary bladder (Fig. 1), not primary
resectable by TURBT due to its large extension. CT-
graphic imaging revealed an exophytic tumor with a
maximum diameter of 7 cm with invasive appearance.
Microscopically (Fig. 2A), extensive infiltrates of myofi-
broblastic proliferation were found, accompanied by
numerous inflammatory cells and variable stromal myxoid
and oedematous change. Several mitotic figures could be
seen, without however atypical forms. There was no
tumor necrosis or pleomorphy. Immunohistochemistry
demonstrated diffuse expression of smooth muscle actin
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and focal positivity for cytokeratins, while desmin, S100
and CD34 were negative (not shown), leading to the sus-
picion of an inflammatory myofibroblastic tumor. The
immunohistochemistry for ALK1 (5A4) protein was
strongly and diffusely positive (Fig. 2B).
The tumor was analyzed by next generation sequencing
using the RNA based Fusion Plex Sarcoma Panel
(Supplementary Table 1). We identified a Fibronectin 1
(FN1) - ALK gene fusion (Fig. 3).
A neoadjuvant therapy with the first generation ALK
inhibitor crizotinib was started to reduce tumor volume
and thus enabling organ sparing resection. No response
was observed after 2 and 4 months of treatment. To inves-
tigate the presence of an ALK mutation conferring resis-
tance to crizotinib we performed the DNA-based part of
the Oncomine Focus Assay (Supplementary Table 2) on
the same pretreatment tumor material with the gene
fusion. No known ALK resistance or any other mutation
or copy number variant was identified by this assay
(Supplementary Table 3).
After switching the medication to the next generation
ALK inhibitor lorlatinib, a rapid response with a partial
remission was seen within 5 weeks (Fig. 4).
Unfortunately, the patient started to complain about
shortness of breath. A chest CT showed bilateral ground
glass opacities, therefore, a pneumonitis was suspected.
Lorlatinib was stopped, and the patient was started on cor-
ticosteroids, leading to a rapid clinical and radiological
improvement. The partial remission to lorlatinib allowed
a bladder sparing operative approach. Through the follow-
ing laparoscopic robot-assisted partial cystectomy, a path-
ologic R0-resection was achieved. Histologically, residual
cells of the IMT with signs of regression were seen. During
a follow-up of 12 months, we found no evidence of recur-
rence or metastases in cystoscopy or imaging.
DISCUSSION
Genomic rearrangements involving ALK gene fusion with
about 30 different partners have been described in a broad
spectrum of malignancies. They are best known in certain
lymphomas and in adenocarcinomas of the lung.7 Our
case was characterized by a FN1 (Fibronectin1)-ALK
gene fusion, which has been found previously in a 12-
year-old male with an IMT of the bladder.8
In several case reports and phase 1b/phase 2 studies,
responses of ALK positive IMTs to crizotinib have been
shown, with an overall response rate of 50%-86%, includ-
ing complete responses in 36% and partial responses in
50% of patients.9-12 Crizotinib is therefore the standard of
care for patients with unresectable ALK mutated IMT.
Remarkably, the tumor of our patient did not respond to a
neoadjuvant treatment with the first generation ALK
inhibitor crizotinib, but reacted with a rapid and deep
response to the next generation ALK inhibitor lorlatinib.
To our knowledge, this is the first case of an IMT showing
a differential response to distinct ALK inhibitors. It is
noteworthy that a grade 3 pneumonitis developed only
with the therapeutically successful tyrosine kinase inhibi-
tor (TKI) lorlatinib, but not with crizotinib.
It is known that a resistance to first generation TKIs can
occur after some months of therapy, due to development
of secondary mutations or activation of bypass pathways.
Figure 1. Initial macroscopic aspect in cystoscopy. (Color
version available online.)
Figure 2. Histopathology of the tumor sample: (A) Myofibroblastic spindle cell proliferation with slightly oedematous myxoid
background and inflammatory infiltrate (HE stain; original magnification 200x). (B) Immunohistochemistry showed diffuse
and strong expression of ALK1 protein (5A4 antibody) in all tumor cells, leading to the diagnosis of an IMT (original magnifica-
tion 100x). (Color version available online.)
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To address this problem, next generation TKIs have been
developed.13,14 Some well-known resistance mutations
(missense or insertion mutations) against the first genera-
tion TKI crizotinib are L1196M, G1202R, S1206C/Y,
C1156Y/T, L1152P/R, I1171T/N, F1174C/L/V, G1269A/
S, V1180L, F1245C, and 1151Tins.13-15 In our patient,
none of these resistance mutations were detected
(Supplementary Table 3), thus the mechanism of resis-
tance to crizotinib remains unclear. In vitro, tumor cells
expressing FN1-ALK had a significantly higher sensitivity
to lorlatinib compared to crizotinib (half maximal inhibi-
tory concentration IC50 of 35 nM vs. 153 nM, respec-
tively).7 It is interesting that the FN1-ALK fusion protein
is the only fusion protein, which retains the transmem-
brane domain and has one of the highest kinase activity
of all ALK fusion partners.7 From a biochemical perspec-
tive, it is not entirely clear why different ALK fusion var-
iants have different sensitivities to ALK TKI therapies,
because each ALK fusion protein contains the entire ALK
tyrosine kinase domain and should theoretically respond
to TKI. Perhaps the various ALK fusion partners have dif-
ferent biochemical and cellular properties and affect
kinase activity, protein stability or tertiary structure, thus
differentially influencing the activity of the various TKI.
Our case indicates that ALK positive IMTs, which do
not respond to ALK inhibition with crizotinib, might not
be refractory to ALK inhibition but can be successfully
treated with newer agents. This could be of importance
both in the neoadjuvant and in the palliative setting espe-
cially to prevent radical intervention and sustain bladder
function.
Prospective therapeutic studies should include the
determination of the involved ALK fusion partners in
order to improve the knowledge about the mechanism of
action and the efficacy of ALK TKIs in the treatment for
IMTs.
Figure 3. Schematic depiction of the gene fusion found in the tumor. Exon 36 of FN1 (in red) fused with Exon 19 of ALK (in
blue). The blue and red arrows show the direction of transcription. The black arrows show the 5’ and 3’ end of unmutated
and fusion transcripts as well as the breakpoints in the unmutated and fusion points in the mutated transcripts. The fusion
transcript downstream of the fusion point was in frame. (Color version available online.)
Figure 4. (A) CT of the pelvis showing the tumor in the bladder (maximum diameter of 7 cm) before treatment. (B) Partial
remission of the tumor (3.3 cm) after therapy with lorlatinib.
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SUPPLEMENTARY MATERIALS
Supplementary material associated with this article can
be found in the online version at https://doi.org/10.1016/
j.urology.2020.09.026.
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